Month: September 2026

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — J. P. Morgan Asset Management (JPMAM)* today announced the final September 2026 cash distributions for the below listed JPMorgan ETFs. The JPMorgan ETFs trade on the Toronto Stock Exchange (TSX). Unitholders of record on October 1, 2026 will receive cash distributions payable on October 7, 2026. Details of the “per unit” distributions are as follows:

JPMorgan ETF name	Ticker symbol	Distribution per unit ($)	Payment frequency
JPMorgan US Equity Premium Income Active ETF	JEPI	0.14594	Monthly
JPMorgan Nasdaq Equity Premium Income Active ETF	JEPQ	0.27751	Monthly
JPMorgan US Equity Premium Income Active ETF – CAD Hedged	JEPH	0.15107	Monthly
JPMorgan Nasdaq Equity Premium Income Active ETF – CAD Hedged	JPQH	0.21248	Monthly
JPMorgan US Value Active ETF	JAVA	0.06043	Quarterly
JPMorgan US Core Active ETF	JCOR	0.02571	Quarterly

To learn more about the JPMorgan ETFs, please visit www.jpmorgan.com/ca/advisors

For more information, please e-mail: jpmam.canada@jpmorgan.com

About J.P. Morgan Asset Management

J.P. Morgan Asset Management, with assets under management of US$4.4 Trillion¹ (as of December 31, 2025), is a global leader in investment management. J.P. Morgan Asset Management’s clients include institutions, retail investors and high net worth individuals in every major market throughout the world. J.P. Morgan Asset Management offers global investment management in equities, fixed income, real estate, hedge funds, private equity and liquidity. For more information: www.jpmorganassetmanagement.com.

* Legal entity in Canada: JPMorgan Asset Management (Canada) Inc.

¹ Source: J.P. Morgan Asset Management, as of December 30, 2025.

Commissions, trailing commissions, management fees and expenses all may be associated with ETF investments. Please read the prospectus before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated.

Past returns are not necessarily indicative of future performance. You should not rely on or view any past performance as a guarantee of future investment performance.

Nasdaq^®, Nasdaq-100 Index^®, Nasdaq 100^® and NDX^® are registered trademarks of Nasdaq, Inc. (which with its affiliates is referred to as the “Corporations”) and are licensed for use by J.P. Morgan Asset Management (Canada) Inc. and J.P. Morgan Investment Management Inc. JPMorgan Nasdaq Equity Premium Income Active ETF has not been passed on by the Corporations as to its legality or suitability. This ETF is not issued, endorsed, sold, or promoted by the Corporations. THE CORPORATIONS MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO THIS ETF.

This communication is issued in Canada, by JPMorgan Asset Management (Canada) Inc. is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon, and an Investment Fund Manager in British Columbia, Ontario, Quebec, and Newfoundland and Labrador. It is also a Derivatives Adviser in Manitoba, a Commodity Trading Manager in Ontario, and a Derivatives Portfolio Manager in Quebec.​

J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November 

CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren’s disease in December

CLN-049 (FLT3 TCE) updated data from the Phase 1 dose escalation study in December

CAMBRIDGE, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today outlined fourth quarter 2026 milestones across its immunology and oncology pipeline.

“We look forward to providing several updates across our T cell engager programs in the fourth quarter of 2026. Starting with autoimmune diseases, for CLN-978 we look forward to sharing the most comprehensive clinical data set to date for a CD19 T cell engager across all indications, with multi-dose regimen data reported concurrently for SLE, RA, and now Sjögren’s disease also. For velinotamig, we will provide multi-dose regimen data from the ongoing Phase 1 dose escalation study as we advance the program in plasma cell driven diseases. Together, our CD19- and BCMA-targeted programs reflect a differentiated approach to treating autoimmune diseases, aiming to address distinct disease drivers across a broad range of conditions. For CLN-049, we plan to provide an update with longer follow up from the dose escalation portion of our ongoing Phase 1 study in a broad, all-comer population of relapsed/refractory AML patients. We look forward to rapidly progressing this program and initiating our potentially registrational Phase 2 study, following our recent successful meeting with the FDA,” said Nadim Ahmed, President and CEO of Cullinan Therapeutics.

The Company plans to share the following immunology and oncology pipeline updates in Q4 2026:

• CLN-978 (CD19xCD3 T cell engager): treatment-refractory moderate to severe systemic lupus erythematosus (SLE), difficult-to-treat rheumatoid arthritis (RA), and treatment-refractory moderate to severe Sjögren’s disease (SjD)
  • Multi-dose and single target dose regimen data in SLE, RA, and SjD in December

• Velinotamig (BCMAxCD3 T cell engager): treatment-refractory autoimmune diseases driven by long-lived plasma cells
  • Multi-dose regimen data from the ongoing Genrix Bio Phase 1 dose escalation study in SLE to be shared in poster session at ACR Convergence 2026 on November 8, 2026, 10:30 a.m. to 12:30 p.m. ET

• CLN-049 (FLT3xCD3 T cell engager): relapsed/refractory acute myeloid leukemia (AML)
  • Updated data from the dose escalation portion of the Phase 1 study in December

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: our clinical development plans and anticipated timelines for our product candidates, the clinical and therapeutic potential of our product candidates, our plans regarding future data presentations and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of clinical trial data and regulatory submissions; the risk that any NDAs, INDs, or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not accepted or cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will not be predictive of future results in connection with future studies or clinical trials; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts:

Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com

Media 
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com

• Completion of vertical construction marks major milestone for first-in-the-nation commercial scale advanced nuclear fuel fabrication facility
• Project advances into interior buildout, fuel fabrication equipment installation and construction of supporting facilities

OAK RIDGE, Tenn., Sept. 24, 2026 (GLOBE NEWSWIRE) — TRISO-X, LLC (“TRISO-X” or the “Company”), a wholly-owned subsidiary of X-Energy, Inc. (Nasdaq: XE) (“X-energy”), today announced the completion of vertical construction at TX-1, its first-in-the-nation advanced nuclear fuel fabrication facility in Oak Ridge, Tennessee. The milestone completes the primary building structure of the 214,000-square-foot facility and enables the project to advance fully into its next phase of construction, including interior buildout, installation of fuel fabrication equipment and continued construction of supporting facilities.

“Completing vertical construction is a major milestone for TX-1 and another tangible demonstration of the progress our team is making in Oak Ridge,” said Joel Duling, President of TRISO-X. “We are moving from constructing the core and shell of the facility to building out the interior utilities, installing manufacturing equipment, and constructing key support capabilities. Every milestone brings us closer to establishing a new domestic source of advanced nuclear fuel and supporting the deployment of the next generation of American nuclear reactors.”

Clark Construction Group continues to serve as construction contractor, leading interior buildout of the facility’s process equipment and administration building, installation of fuel fabrication equipment, and construction of an adjacent graphite matrix powder building. Last month, TRISO-X announced that it had initiated elements of this next phase as vertical construction neared completion. With the structure now complete, construction activity shifts to the systems, equipment and infrastructure required to prepare TX-1 for commercial operations.

Once operational, TX-1 is expected to produce approximately 700,000 TRISO-X fuel pebbles annually, equivalent to 5 metric tons of uranium (“MTU”), with capacity to provide fuel for up to 11 Xe-100 reactors. The U.S. Nuclear Regulatory Commission (“NRC”) granted TRISO-X a 40-year Special Nuclear Material License for the facility earlier this year, the first-ever NRC Category 2 fuel fabrication license issued for the processing of high-assay low-enriched uranium. TX-1 is expected to be the first new commercial-scale advanced U.S. nuclear fuel fabrication facility built in more than 50 years.

The completion of vertical construction builds on a period of sustained progress across TRISO-X’s Oak Ridge operations. In recent months, the Company expanded its nuclear fuel campus by approximately 70 acres, extended its cooperative research and development relationship with Oak Ridge National Laboratory, initiated construction of TX-L, a dedicated research and development facility, and received economic development support from the State of Tennessee for continued expansion of its advanced nuclear fuel campus.

TX-1 is being developed initially to support X-energy’s proposed deployment of its Xe-100 advanced small modular reactor at Dow Inc.’s UCC Seadrift Operations manufacturing site in Texas through the U.S. Department of Energy’s Advanced Reactor Demonstration Program. X-energy is also advancing additional Xe-100 projects in partnership with Energy Northwest, Amazon, and Centrica as demand grows for secure, reliable, and scalable nuclear energy.

About X-energy

X-energy is a leading designer of advanced small modular nuclear reactors (“SMR”) and fuel technology developed to establish a new standard in clean, safe, reliable energy. X-energy’s intrinsically safe Xe-100 high-temperature gas-cooled reactor and TRISO-X particle fuel expand applications for nuclear technology, with commercial projects across grid, industrial, and AI. Together, X-energy’s technology drives enhanced safety, lower cost, faster construction timelines, and scalable deployment when compared with other SMRs and conventional nuclear. For more information, visit X-energy.com or connect with us on X or LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which X-energy and its subsidiary TRISO-X intend to be covered by the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “will,” “seek,” the negative of these words, or similar terms may identify forward-looking statements, but their absence does not mean a statement is not forward-looking. These include, but are not limited to, statements regarding the next phase of TX-1 construction; TX-1’s expected capacity; the expected benefits of the Company’s Oak Ridge campus; and the anticipated development and completion of X-energy’s ongoing reactor projects.

You should not rely on these forward-looking statements as predictions of future events. Actual results may differ materially due to a number of factors, including, but not limited to: delays, cost increases, or setbacks in the construction and interior buildout, licensing, or scaling of TX-1 and the Company’s fuel fabrication campus; changes, delays, or inability to obtain and maintain licenses or governmental approvals; supply chain and supplier constraints; and first-of-a-kind risks and the Company’s limited operating experience at intended scale, including latent design or operational issues.

More information about potential risks is detailed under “Risk Factors” in X-energy’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”), and in subsequent SEC filings, available on X-energy’s Investor Relations website at https://investors.x-energy.com/ and on the SEC website at www.sec.gov. Any forward-looking statements herein are based on assumptions believed reasonable as of, and speak only as of, the date of this press release. Except as required by law, X-energy undertakes no obligation to update these statements as a result of new information or future events.

Contact

Robert McEntyre, Corporate Communications
media@x-energy.com
+1 240.673.6565

Patricia Gil, Investor Relations
+1 301.558.3040
investors@x-energy.com

The future self-developed community will introduce 76 new single-family homesites to one of the Lowcountry’s fastest growing and most desirable residential markets

CHARLESTON, S.C., Sept. 24, 2026 (GLOBE NEWSWIRE) — Tri Pointe Homes^®, one of the nation’s largest homebuilders, has acquired 60.4 acres in Bluffton, South Carolina, to develop 76 single-family homesites in the final phase of New Riverside’s 3,600-acre planned residential and mixed-use development. The acquisition supports the company’s continued growth in one of the region’s most sought-after Lowcountry markets.

“This acquisition is an important milestone for our division because it represents one of the last new home opportunities in Bluffton,” said Division President of Tri Pointe Homes – Coastal Carolinas Robert Norton. “South Carolina’s emergence as the fastest-growing state in the nation¹, and Bluffton’s continued recognition as one of the state’s fastest-growing cities², reinforce the long-term opportunity Tri Pointe Homes sees in the Lowcountry. New Riverside captures everything that makes this area so attractive to homebuyers, including its regional connectivity, outdoor recreation, and everyday convenience. We’re thrilled to complement this growth story by delivering the premium lifestyle experience Tri Pointe is known for.”

Tri Pointe’s community will be located within the final phase of New Riverside near the entrance to Palmetto Bluff off New Riverside Road. With home designs currently in development and subject to change, plans anticipate homes up to 3,600 square feet with 2- and 3-bay garage options on expansive homesites. The neighborhood, tucked behind a gated entry, will offer trail connectivity throughout the community that connects into New Riverside Barn Park.

Residents will enjoy convenient access to many of the destinations that make Bluffton one of the Southeast’s most desirable places to live. Historic downtown Bluffton and the May River waterfront are located approximately 10 minutes away, while area beaches, parks, and outdoor recreation can be reached in about 20 minutes. Downtown Savannah, Georgia, is approximately 30 minutes from the site, providing additional employment, entertainment, and cultural opportunities.

A premier submarket in the Hilton Head-Savannah region, Bluffton continues to attract homebuyers with its vibrant local attractions, outdoor recreation, and highly regarded schools. The location is also near public golf courses, public boat ramps, grocery and retail offerings, and the recently constructed New Riverside Village, which features retail, services, and dining options approximately one mile from the site. The community will also benefit from regional trail connectivity through nearby New Riverside Barn Park and its broader trail system.

Development is anticipated to begin in September 2026, with home construction expected to begin in late 2027 and sales projected to launch in 2028.

“We’re designing this community with the way people want to live today in mind,” said Norton. “Our goal is to create homes that capture the essence of the Lowcountry while delivering thoughtful design, quality craftsmanship, and lasting value. We’re proud this investment will support local contractors, trades, suppliers, and businesses while contributing to the continued growth of one of South Carolina’s most dynamic residential markets.”

For more information and updates as the community progresses, please visit https://www.tripointehomes.com/coastal-carolinas.

About Tri Pointe Homes^®
One of the largest homebuilders in the U.S., Tri Pointe Homes, Inc. has a presence in 13 states and the District of Columbia, and is a recognized leader in customer experience, innovative design, and environmentally responsible business practices. The company builds premium homes and communities with deep ties to the communities it serves—some for as long as a century. Tri Pointe Homes combines the financial resources, technology platforms and proven leadership of a national organization with the regional insights, longstanding community connections and agility of empowered local teams. The company is one of the 2026 Fortune World’s Most Admired Companies, 2026 Fortune 100 Best Companies to Work For^®, and recognized as a PEOPLE Companies That Care^® (2023-2026) organization. The company was also named a Great Place To Work-Certified™ company for five years in a row and named on several Great Place To Work® Best Workplaces lists. Tri Pointe has also won multiple Builder of the Year and Developer of the Year awards. TriPointeHomes.com.

¹ Source: U.S. Census Bureau
² Source: World Population Review

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e0bf837-e058-4a8a-851b-ef7577073ca3

CONTACT: Contact
Katy Biggerstaff, NewGround PR & Media
562.761.6338 / kbiggerstaff@newgroundco.com

Exploratory research results presented at Psych Congress 2026 in New Orleans

Full poster presentation can be found on “Publications” section of Company’s website

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, presented positive exploratory data at Psych Congress 2026 in New Orleans. The poster highlights a potential efficacy signal for fasedienol nasal spray, the Company’s rapid-onset Phase 3 product candidate, observed in a public speaking challenge study involving participants with very severe social anxiety disorder.

The research presented by Vistagen in a poster supports fasedienol’s potential for individuals with very severe social anxiety disorder, as defined by a baseline Liebowitz Social Anxiety Scale (LSAS) score of 95 or higher. In subpopulation analyses, one post-hoc and one prespecified, from two randomized, double-blind, placebo-controlled clinical trials, participants with very severe (LSAS >=95) social anxiety disorder experienced improvements in anxiety symptoms following treatment with fasedienol compared with placebo as measured by the Subjective Units of Distress Scale (SUDS).

“The positive potential efficacy signals observed in these analyses of fasedienol in very severe social anxiety disorder participants are encouraging and provide important insights into our understanding of its role in social anxiety disorder,” said Dr. Angel S. Angelov, Chief Medical Officer of Vistagen. “These findings, including the potential benefit of repeat dosing, help inform our ongoing evaluation of fasedienol.”

The post-hoc analysis of the subpopulation of very severe subjects from the randomized, double-blind, placebo-controlled portion of the PALISADE-4 Phase 3 clinical trial showed a statistically significant benefit of fasedienol on average SUDS scores during the public speaking challenge (PSC), although the study did not meet its primary endpoint in the total population. In an exploratory, randomized, double-blind, placebo-controlled Phase 2a repeat dose study (RDS), prespecified analysis of the subpopulation of participants with very severe social anxiety showed a statistically significant improvement following a single dose of fasedienol on average SUDS scores during the PSC, and an even greater numerical improvement after a second dose of intranasal fasedienol taken 10 minutes after the first. Significant improvements on pre-PSC anticipatory anxiety in both the total population and in the very severe population in the RDS also were observed, suggesting a second dose of fasedienol administered 10 minutes after the first could improve anticipatory anxiety.

Favorable safety and tolerability results in the study participants with very severe social anxiety disorder were consistent with the overall population in the two studies presented in the poster and with previous trials, and no serious drug-related safety signals were identified.

To read the full poster, please visit our “Publications” page under “Fasedienol”.

About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at www.vistagen.com.

Forward-looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including, without limitation, the ability of the research presented by Vistagen to support the potential of fasedienol nasal spray as an active drug for individuals with very severe social anxiety disorder and the meaningfulness of the efficacy signals observed in the analyses, including the potential benefit of repeat dosing of fasedienol which remain subject to change upon completion of a full analysis and audit of the complete data set from the study. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain. As with all pharmaceutical products, there are substantial risks and uncertainties in the process of development and commercialization, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. There can be no guarantee that any of Vistagen’s product candidates, including fasedienol, will successfully complete ongoing or future clinical trials within estimated timelines or at all, receive regulatory approval or be commercially successful. These risks and others are more fully discussed in the section entitled “Risk Factors” in Vistagen’s Annual Report on Form 10-K for the period ended March 31, 2026, and Quarterly Report on Form 10-Q for the period ended June 30, 2026, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the U.S. Securities and Exchange Commission (SEC). Vistagen’s SEC filings are available on the SEC’s website at www.sec.gov. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing Vistagen’s views as of any subsequent date. Vistagen explicitly disclaims any obligation to update any forward-looking statements other than as may be required by law. If Vistagen does update one or more forward-looking statements, no inference should be made that Vistagen will make additional updates with respect to those or other forward-looking statements.

Investor Inquiries: 
IR@vistagen.com

Media Inquiries: 
media@vistagen.com

JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies.

Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell pipeline assets, including AVC-201 and AVC-203, with the applicable rate determined based on the total amount ultimately funded. The capital will be funded in four tranches: with the first payable at closing, and the remaining three tranches payable upon achievement of certain predetermined clinical milestones and other specified financing conditions. Ligand has also committed up to $6 million in concomitant Series C financing, details of which will be announced separately.

“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to date with AVC-201, highlights the potential of AvenCell’s platform across a broad range of diseases. We look forward to working closely with the AvenCell team as it advances its pipeline of next-generation cell therapies.”

AvenCell was founded in 2021 combining switchable CAR-T technology developed by GEMoaB GmbH (now AvenCell Europe GmbH) with Intellia’s CRISPR/Cas9-based Allogeneic Engineering Technology to develop next-generation cell therapies designed to overcome key limitations of existing CAR-T treatments. AvenCell’s proprietary platform is designed to enable readily available, “off-the-shelf” cell therapies with greater control over CAR-T activity and the potential for broad application across hematologic malignancies and autoimmune diseases.

The company’s lead program, AVC-201, is an anti-CD123 CAR-T currently in a Ph1b expansion trial for the treatment of relapsed or refractory AML. AvenCell is also advancing AVC-203, a Phase 1a program for B-cell malignancies.

“We are excited to have the support and expertise of the Ligand team as we look to advance our pipeline programs through the clinic,” said Andrew Schiermeier, President & CEO of AvenCell. “This investment provides us critical resources to support the continued development of these potentially important new treatment options for patients impacted by these difficult-to-treat cancers.”

Hogan Lovells Cadwalader served as legal advisor to Ligand.

About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the expected funding and use of proceeds under the financing arrangement; satisfaction of conditions to, and the timing and amount of, future royalty and equity investments; the development, regulatory progress, clinical performance, safety, efficacy, commercial potential and potential indications of AVC-201, AVC-203 and AvenCell’s platform and other products; the potential for AvenCell’s technologies to address limitations of existing CAR-T therapies; future sales of covered products; Ligand’s expected receipt of royalties; and Ligand’s royalty portfolio strategy and expected revenue characteristics. These statements are based on various assumptions and on the current expectations of Ligand’s management and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, many of which are beyond Ligand’s control. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the possibility that conditions to future funding are not satisfied or that optional investments are not made; AvenCell’s ability to use the financing as anticipated and to continue funding its operations and development programs; the preliminary nature of clinical data and the limited number of patients evaluated to date; the possibility that results observed in early-stage clinical trials may not be replicated in later or larger trials; adverse events, safety issues or unfavorable benefit-risk profiles; delays or failures in clinical development, patient enrollment, manufacturing, regulatory interactions or regulatory approvals; the possibility that additional or randomized clinical trials may be required; manufacturing, supply-chain, comparability and scalability challenges associated with cell therapies; competition from existing and future therapies; intellectual property risks, including the possibility that pending patent applications do not issue or provide meaningful protection; Ligand’s reliance on AvenCell, its license partners, manufacturers and other third parties to develop, manufacture and commercialize covered products and to calculate and pay royalties; the possibility that covered products are never approved or commercialized, or that sales are lower than expected; the scope and duration of Ligand’s royalty rights under the definitive agreements; and the other risk factors discussed under the heading “Item 1A. Risk Factors” in Ligand’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 27, 2026, and Ligand’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026, filed with the SEC on May 8, 2026 and August 7, 2026, respectively. Ligand cautions against placing undue reliance on these forward-looking statements, which speak only as of the date of this press release, and undertakes no obligation to update any forward-looking statements except as required by law.

Contacts

Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

Tripled ridership, more than 50% lower cost per ride, and rapid transit infrastructure deployment

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Argo Corporation (TSXV: ARGH) (OTCQX: ARGHF) (“Argo” or the “Company”) today announced that average daily transit ridership in the Town of Bradford West Gwillimbury (“BWG” or the “Town”) has grown to more than 3x the daily ridership of the Town’s previous fixed-route transit system.

Argo launched its proprietary Smart Routing™ transit infrastructure and service in BWG in April 2025. The Town subsequently replaced its previous privately operated fixed-route service with Argo’s on-demand public transit and renewed and expanded its agreement with Argo.

Argo Smart Routing™ Transit in Bradford West Gwillimbury, Canada

• Tripled Ridership: Average daily ridership has grown to more than 3x pre-Argo levels.
• Increased Transit Connections: As previously reported, Argo drove a more than 5x increase in transit connections to Bradford GO.
• Point-to-Point Access: Residents are now picked up where they are and dropped off where they are going, with over 90% of Argo trips including a pickup or drop-off more than 100 metres from the previous fixed-route bus stops.
• Lower Cost per Ride: As previously reported, the Town’s cost per ride declined by more than 50% compared with its previous fixed-route service.
• Rapid Deployment: Argo launched the infrastructure, technology and operations required for Smart Routing™ approximately three months from contract signing.
• Provincial Funding: Ontario has awarded BWG $4,093,337 through the Ontario Transit Investment Fund to support further expansion of on-demand transit.

“Bradford shows how modern transit technology can expand access to opportunity and independence, and give people the freedom to participate fully in their communities,” said Praveen Arichandran, Co-founder and CEO of Argo. “We’re bringing integrated transit infrastructure and operations online in weeks, not years, so more people can realize those benefits sooner.”

Since the BWG launch, Argo has continued the expansion of its Smart Routing™ network in Brampton and Caledon. The Company’s focus remains on expanding the network across Canada, the United States, and internationally.

About Argo

Argo delivers the first-ever vertically and publicly integrated city transit system, designed to augment public transportation and create a network of intelligently routed vehicles that work together to serve and scale to the needs of entire cities, putting people in control of their mobility. Learn more at www.rideargo.com.

Investor Contact Praveen Arichandran Co-founder & CEO Argo Corporation (800) 575-7051	Media Contact Christina Ra Argo Corporation christina@rideargo.com (800) 575-7051

Forward-Looking Information

This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. The forward-looking information set out in this news release relates to future events or future performance and includes, without limitation, statements concerning the continued operation and expansion of Smart Routing™ in Bradford West Gwillimbury, the use of provincial funding to support further expansion of on-demand transit, the anticipated benefits of Argo’s Smart Routing™ transit system, potential future expansion to other municipalities, and the Company’s plans to expand its network in Canada, the United States and internationally, the Company’s deployment timelines.

Such forward-looking statements are based on a number of assumptions, including: the continued successful operation of the Bradford West Gwillimbury service; maintaining municipal agreements in good standing; receiving required third-party approvals, consents and integrations; operational readiness; ridership adoption levels; technology performance and reliability; the availability and use of government funding; the availability of municipal procurement opportunities and execution of definitive agreements with new municipalities; and general economic conditions. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including but not limited to: operational challenges; failure to meet contractual requirements; loss of required operating authority, insurance or approvals; third-party integration delays or failures; technology failures or cybersecurity incidents; termination or non-renewal of municipal agreements; failure to secure new municipal contracts; regulatory changes; availability of financing; and general economic conditions. Additional risks and uncertainties are described in more detail in the Company’s securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and readers are cautioned against placing undue reliance thereon. The Company assumes no obligation to revise or update these forward-looking statements except as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a8d2001-14f6-42a3-b0f6-87401547a9eb

Integrated exploration model identifies multiple priority epithermal and porphyry targets across Fishpot; ~2,000-metre maiden drill program prepares for launch; Company commences trading on OTCQB under INXGF

VANCOUVER, British Columbia, Sept. 24, 2026 (GLOBE NEWSWIRE) — GoldInxs Mining Corp. (“GoldInxs,” or the “Company”) (TSXV: INXS, OTCQB: INXGF) is pleased to announce it has received results from a 53.4-line-kilometre 3D Induced Polarization (“IP”) survey, reprocessed Airborne Magnetic Survey data and a Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) survey on its flagship Fishpot property in Central British Columbia. The combined results have refined multiple priority exploration targets where geophysical responses coincide with surface geology, alteration and geochemical anomalies ahead of the Company’s planned ~2,000-metre maiden drill program.

The Company is also pleased to report that its common shares have commenced trading on the OTCQB Venture Market under the symbol “INXGF“, an important step in broadening GoldInxs’ shareholder base, enhancing accessibility for U.S. investors and providing an additional platform for market visibility as the Company advances its exploration programs in British Columbia.

The integrated geophysical results identified and refined multiple chargeability, resistivity and magnetic features that correlate with existing geological, alteration and surface geochemical information, providing the Company with a more robust framework for prioritizing drill targets ahead of its planned ~2,000-metre maiden drill program. The Virtual DRILL™ Elemental Harmonic Resonance (“EHR”) survey also correlates with the updated geophysical results, resulting in robust multi-discipline exploration targets (refer to the Company’s press release dated August 17, 2026). The Company continues to plan and prepare for its inaugural drill program at Fishpot, located in the broader regional setting of Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property, providing exposure to an active and increasingly established gold exploration region.

Key Highlights

• 53.4 line-kilometer 3D IP survey identified multiple chargeability and resistivity anomalies across the Fishpot property, including responses that correlate with existing surface geology, alteration and geochemical anomalies;
• Airborne magnetic data successfully reprocessed using Magnetization Vector Intensity (“MVI”), improving interpretation of magnetic responses in areas affected by magnetic remanence;
• Virtual DRILL™ Elemental Harmonic Resonance results correlate strongly with the existing and new data, showing its potential for use on other parts of the property;
• New geophysical information evaluated as part of an integrated exploration model combining 3D IP chargeability and resistivity responses with magnetic data, Virtual DRILL™ data, geological mapping, alteration and surface geochemistry, refining priority target zones based on areas where multiple exploration datasets converge;
• Planning and targeting continues for a ~2,000-metre maiden drill program, with drill pad locations and hole orientations being finalized based on the integrated geological and geophysical model.

3D Induced Polarization Results

In late July 2026, the Company engaged SJ Geophysics to complete a 3D IP survey on the Fishpot property. Data was acquired from July 28^th to August 19^th over 53.4 line kilometers in 8 lines overlapping with the main mineralized zones on the property. Results show large zones of subsurface resistivity and chargeability anomalies, many of which correlate with the surface geochemical anomalies and geology. Of particular note is the overlapping resistivity and chargeability anomalies that underlie the Lightening Zone, as well as the chargeability high, magnetic low zone that surrounds the previously identified magnetic high “lobe”, now known as the BullsEye target. The circular magnetic and chargeability response at BullsEye is considered a priority feature for follow-up exploration and may be consistent with geological characteristics observed in copper porphyry systems; drilling will be required to test this interpretation.

The 3D IP survey provides an important additional layer of subsurface information to complement the Company’s existing surface exploration dataset. Of particular interest are areas where IP responses coincide spatially with mapped geological contacts, alteration zones and anomalous surface geochemistry. The Company believes these areas warrant additional investigation and have contributed significantly to the prioritization of drill targets for the upcoming maiden drill program.

Magnetic Survey Reprocessing Results

The previously collected airborne magnetic, radiometric, and VLF-EM survey data obtained in 2025 was provided to in3D Geoscience Inc. who reprocessed the data using Magnetization Vector Intensity (“MVI”). MVI re-models the data to reduce the impacts of magnetic remanence, which can cause certain anomalies to be offset from their true locations. Several zones of magnetic remanence were identified in the original data and the resultant MVI model improved accuracy of the data in those areas.

Virtual DRILL™

The Company has received the results from the Virtual DRILL™ EHR survey. Several target areas have been identified which correlate to the existing and newly acquired exploration data. The Virtual DRILL™ EHR survey was completed independently of the newly acquired 3D IP and reprocessed magnetic data. Several EHR target areas subsequently demonstrated spatial correlation with the updated geophysical and existing geological datasets, providing an additional layer of target validation. The maiden drill program will provide an opportunity to test selected EHR targets against conventional geological and geophysical interpretations.

The Company has now integrated six exploration datasets at Fishpot; IP chargeability, IP resistivity, magnetic data, Virtual DRILL™ EHR results, geological mapping, alteration and surface geochemistry, to prioritize areas where multiple indicators overlap.

Figure 1: Induced Polarization Survey results showing Resistivity and Chargeability.

Figure 2: Magnetics MVI reprocessing results and Virtual Drill EHR results

Drill Planning Update

Integrating the new and reprocessed geophysical data with the existing property data has allowed the Company to refine their drill targets ahead of the maiden drill program planned for the Fishpot property. Overlapping geological surface information, including geochemistry, alteration, and geological mapping data with new and updated geophysical data has highlighted several promising surface and subsurface anomalies on the property. In light of the new anomalies, the Company has created several identified priority gold-silver epithermal target zones including the ‘Lightening’ zone, the ‘Luftballon’ zone’, the ‘Thriller’ zone, the ‘Believin’ zone, the “Southside’ zone, and a copper porphyry target called the ‘BullsEye’. Further refinement will be ongoing as it relates to specific drill pad locations until drilling commences, and modifications may be made as the drill program progresses.

• Lightening Zone: Resistivity and chargeability IP anomaly overlain by intense silica alteration and overlapping geochemical anomalies.
• Luftballon Zone: Magnetic low with a moderate chargeability anomaly located north of the magnetic high lobe. Intense silica alteration with overlapping geochemical anomalies.
• Thriller Zone: Magnetic low zone with resistivity anomaly, silica “ribs” present on surface.
• Believin’ Zone: Resistivity high zone with moderate chargeability anomaly and overlapping magnetic low.
• Southside Zone: Moderate chargeability high with resistivity high contact, south side of the circular magnetic lobe.
• BullsEye: Magnetic high zone surrounded by magnetic low with moderate chargeability anomaly.

Figure 3: Fishpot exploration target areas

The maiden drill program is being designed to test multiple geological and geophysical targets across the property and provide the Company with its first systematic subsurface drilling dataset at Fishpot. Results from the drill program are expected to provide important information regarding geometry, continuity, geological controls and potential scale of mineralized systems identified through surface exploration and geophysical interpretation.

Millar Property

GoldInxs has decided to drop its interests in the Millar Property in order to focus resources on its core, road accessible and drill ready Fishpot Project given the near-term catalysts and discovery potential. The Company is actively pursuing other acquisitions of properties in North America.

Nick Michael, President and CEO of GoldInxs, commented:

“The Induced Polarization results represent one of the final pieces of information needed to further refine our drill targeting. The data has identified several compelling targets and strengthened our confidence in the areas we have prioritized for drilling. Most importantly, we are seeing strong convergence across multiple exploration datasets, allowing us to move from broad target generation to a focused maiden drill program designed to test some of the most compelling targets identified at Fishpot.The commencement of trading on the OTCQB is also an important corporate milestone for GoldInxs, supporting and improving the Company’s visibility and liquidity. It expands the Company’s accessibility to U.S. investors at an exciting stage in our exploration program, as we transition from systematic target generation toward the first drill testing at Fishpot.”

Qualified Person

The technical information contained in this news release has been reviewed and approved by Darcy Vis, P.Geo., the Qualified Person for GoldInxs Mining Corp., who is responsible for the technical information contained herein. The Company’s corporate presentation identifies Mr. Vis as the Qualified Person responsible for the technical information presented by GoldInxs.

Authorised for release by the Board of GoldInxs Mining Corp.

About GoldInxs

GoldInxs Mining Corp. (TSXV:INXS, OTCQB: INXGF) is a Canadian mineral exploration company focused on discovering and advancing a high-quality gold and copper project in Central British Columbia. The Company’s flagship asset is the Fishpot Property, a large epithermal gold system in central British Columbia with Blackwater-style exploration potential, and in the same region as Artemis Gold’s Blackwater Mine and Evolution Mining’s optioned Clisbako property. The Company is listed on the TSX Venture Exchange under the symbol INXS and on the OTCQB Venture Market under the symbol INXGF, and is led by an experienced management and technical team committed to disciplined exploration and value creation for shareholders.

Website: www.goldinxs.com      |     LinkedIn: LINK      |     Twitter/X: LINK

Further Information:

Barry Miller                        
Executive Chairman and Director
GoldInxs Mining Corp.
T: 778.232.1878
E: barry@goldinxs.com

Forward-Looking Statements

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements are based on a number of assumptions, which may prove to be incorrect. Assumptions have been made regarding, among other things: conditions in general economic and financial markets; accuracy of assay results; geological interpretations from exploration, survey, historic work, drilling results, timing and amount of capital expenditures; performance of available laboratory and other related services; future operating costs; and the historical basis for current estimates of potential quantities and grades of target zones. The actual results could differ materially from those anticipated in these forward-looking statements as a result of risk factors, including the timing and content of work programs; results of exploration activities and development of mineral properties; the interpretation and uncertainties of drilling results and other geological data; receipt, maintenance and security of permits and mineral property titles; environmental and other regulatory risks; project costs overruns or unanticipated costs and expenses; availability of funds; failure to delineate potential quantities and grades of the target zones based on historical data; and general market and industry conditions.

Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company’s planned exploration activities at the Fishpot Property or any other Company properties, the timing, scope and objectives of the planned maiden drill program, the anticipated usefulness of geological, geochemical and geophysical data in refining exploration targets, potential exploration results, other prospective exploration projects, regional considerations, potential future financings of the Company and the potential benefits of the Company’s listing on the OTCQB Venture Market.

The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statements were made. The Company undertakes no obligation to update or revise any forward-looking statements included in this news release if these beliefs, estimates and opinions or other circumstances should change, except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/bfe5c0b8-9313-45b3-b711-262ed618d0b8

https://www.globenewswire.com/NewsRoom/AttachmentNg/2ed00ce5-97be-4d3b-9605-544a5458b544

https://www.globenewswire.com/NewsRoom/AttachmentNg/be70e054-86fd-4d61-991f-119a8edb9357 

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil^® (remestemcel-L-rknd).

The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or production in new facilities. This assay will be used as part of a matrix to release each commercial batch of RYONCIL in conjunction with the existing potency assays which determine IL-2Rα inhibition and CAP (Cell Adhesion and Proliferation), as per the product’s Biologics License. Together these assays ensure that the RYONCIL product is consistent, potent, and clinically effective.

RYONCIL is the first industrially-manufactured allogeneic MSC product approved by FDA for any indication, and the only MSC product to be approved for patients with steroid-refractory acute graft versus host disease (SR-aGvHD) aged 2 months or older.¹ Mesoblast and FDA have been working closely together since RYONCIL was approved for commercial use to ensure alignment on continued advancements to the product’s manufacturing processes and implementation of assays measuring the product’s ongoing quality control.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s Ryoncil^® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil^® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and X: @Mesoblast

Footnotes / References

1. Please see the full Prescribing Information at www.ryoncil.com

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

Corporate Communications / Investors
Paul Hughes
T: +61 3 9639 6036
Media – Global	Media – Australia
Rubenstein	BlueDot Media
Caroline Nelson	Steve Dabkowski
T: +1 703 489 3037	T: +61 419 880 486
E: cnelson@rubenstein.com	E: steve@bluedot.net.au